StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, Maxim Group reiterated a “hold” rating on shares of Galmed Pharmaceuticals in a research report on Friday, April 4th.

Galmed Pharmaceuticals Price Performance

Galmed Pharmaceuticals stock opened at $1.25 on Wednesday. The firm has a fifty day simple moving average of $1.59 and a two-hundred day simple moving average of $2.46. Galmed Pharmaceuticals has a twelve month low of $1.15 and a twelve month high of $23.80. The company has a market capitalization of $2.07 million, a PE ratio of -0.08 and a beta of 0.49.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 76.14% of the stock is owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.